International Medical Journal, Vol. 22., Iss. 1, 2016, P. 61−67.
THE EXPERIENCE OF COMPLEX TREATMENT FOR PAIN SYNDROME AGAINST A BACKGROUND OF DYSPHAGIA
Kharkiv National Medical University, Ukraine
Pain syndrome is present in numerous cases in neurology and maxillofacial surgery. One of the universal kinds of medication, relating to the group of symptom−modifying drugs that treat pain syndrome, are nonsteroid anti−inflammatory drugs in various doses. However, the patients with acute impairments and chronic dysfunctions of brain blood circulation often acquire bulbar and pseudobulbar dysfunction, characterized by development of dysphagia, various inflammatory infectious processes, traumas requiring immobilization and resulting in pain syndrome in the maxillofacial area, which makes the operation of muscles involved in chewing and swallowing more difficult. A powerful drug with anti−inflammatory, analgesic, and antipyretic effects is meloxicam in the form of orally disintegrating tablets (Movixicam® ODT), which dissolve in the patient's mouth and do not require active involvement of the muscles. The research showed high efficiency of Movixicam® ODT while treating patients with pain syndrome of varying etiology caused by dysphagia. Positive therapeutic effects of varying degrees could be observed in 98 per cent of cases, which meant a considerable decrease in the intensity of pain syndrome, which meant a higher degree of the freedom of movement of the patients' muscles. The convenience of applying the orally disintegrating form of meloxicam widens its range of application and allows its administration even in the cases of dysphagia.
Key words: pain syndrome, dysphagia, Movixicam(r) ODT.